ArticleJournal of cancer research and clinical oncology2025
Transcriptional regulation of nucleotide metabolism in medulloblastoma subtypes and prognostic implications analyzed by RNA-Seq.
Article in Journal of cancer research and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveSubtypes of medulloblastoma (MB), WNT, SHH, Group 3 and Group 4, have different prognoses and the impact of abnormal nucleotide metabolism remains unclear. Multi-omics data was integrated to analyze the effect of nucleotide metabolism genes on MB molecular characteristics, prognosis and drug sensitivity. The aim was to identify subtype-specific therapeutic targets to inform treatment.
methodsA total of 132 MB samples datasets were accessed, UMAP and hierarchical clustering analysis were performed using the expression profiles of 1804 nucleotide metabolism genes and association with molecular subtype was evaluated. Genes were screened and prognostic signatures constructed by univariate Cox regression, cross-validation and LASSO-Cox regression and predictive efficacy was verified in training and independent validation sets. Pharmacogenomic data were combined to predict differences in drug sensitivity between high- and low-risk groups.
resultsNucleotide metabolism gene expression profiles were distinct among the four major MB subtypes, indicating coupling of metabolic reprogramming and tumor lineage. 51 prognostic genes were screened and were involved in RNA splicing, anatomical structure maintenance and purine compound metabolism. A signature was constructed from 17 nucleotide metabolism genes which distinguished high from low-risk (p < 0.001) groups and gave an independent prognosis in multivariate analysis. Drug sensitivity analysis showed the high-risk group to be more sensitive to MEK/ERK inhibitors and the low-risk group to PLK1, IGF1R/IR, ROCK and mTORC1/2 inhibitors.
conclusionNucleotide metabolism-transcription coupling endows MB subtypes with heterogeneity and affects prognosis. The signature is a quantitative tool for individualized risk assessment and metabolism targeted therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.